165 related articles for article (PubMed ID: 18809221)
41. In vivo activity of leflunomide: pharmacokinetic analyses and mechanism of immunosuppression.
Chong AS; Huang W; Liu W; Luo J; Shen J; Xu W; Ma L; Blinder L; Xiao F; Xu X; Clardy C; Foster P; Williams JA
Transplantation; 1999 Jul; 68(1):100-9. PubMed ID: 10428276
[TBL] [Abstract][Full Text] [Related]
42. Conjugated bile acids promote ERK1/2 and AKT activation via a pertussis toxin-sensitive mechanism in murine and human hepatocytes.
Dent P; Fang Y; Gupta S; Studer E; Mitchell C; Spiegel S; Hylemon PB
Hepatology; 2005 Dec; 42(6):1291-9. PubMed ID: 16317705
[TBL] [Abstract][Full Text] [Related]
43. Pregnane X receptor activation protects rat hepatocytes against deoxycholic acid-induced apoptosis.
Zucchini-Pascal N; de Sousa G; Pizzol J; Rahmani R
Liver Int; 2010 Feb; 30(2):284-97. PubMed ID: 19737350
[TBL] [Abstract][Full Text] [Related]
44. [Inhibition of leflunomide active metabolite A771726 on high glucose-induced podocyte apoptosis].
Yuan YC; Yu WM; Li RS; Qiao X
Zhonghua Yi Xue Za Zhi; 2011 Mar; 91(10):703-6. PubMed ID: 21600180
[TBL] [Abstract][Full Text] [Related]
45. The immunosuppressive metabolite of leflunomide, A77 1726, affects murine T cells through two biochemical mechanisms.
Elder RT; Xu X; Williams JW; Gong H; Finnegan A; Chong AS
J Immunol; 1997 Jul; 159(1):22-7. PubMed ID: 9200434
[TBL] [Abstract][Full Text] [Related]
46. Inhibition of HIV replication by A77 1726, the active metabolite of leflunomide, in combination with pyrimidine nucleoside reverse transcriptase inhibitors.
Hossain MM; Margolis DM
J Acquir Immune Defic Syndr; 2001 Oct; 28(2):199-201. PubMed ID: 11588518
[No Abstract] [Full Text] [Related]
47. Effects of leflunomide (HWA 486) on expression of lymphocyte activation markers.
Zielinski T; Müller HJ; Bartlett RR
Agents Actions; 1993; 38 Spec No():C80-2. PubMed ID: 8317329
[TBL] [Abstract][Full Text] [Related]
48. Leflunomide inhibits activation of inducible nitric oxide synthase in rat astrocytes.
Miljkovic D; Samardzic T; Mostarica Stojkovic M; Stosic-Grujicic S; Popadic D; Trajkovic V
Brain Res; 2001 Jan; 889(1-2):331-8. PubMed ID: 11166726
[TBL] [Abstract][Full Text] [Related]
49. The active metabolite of leflunomide, A771726, inhibits both the generation of and the bone-resorbing activity of osteoclasts by acting directly on cells of the osteoclast lineage.
Kobayashi Y; Ueyama S; Arai Y; Yoshida Y; Kaneda T; Sato T; Shin K; Kumegawa M; Hakeda Y
J Bone Miner Metab; 2004; 22(4):318-28. PubMed ID: 15221489
[TBL] [Abstract][Full Text] [Related]
50. Therapeutic drug monitoring of A77 1726, the active metabolite of leflunomide: serum concentrations predict response to treatment in patients with rheumatoid arthritis.
van Roon EN; Jansen TL; van de Laar MA; Janssen M; Yska JP; Keuper R; Houtman PM; Brouwers JR
Ann Rheum Dis; 2005 Apr; 64(4):569-74. PubMed ID: 15345501
[TBL] [Abstract][Full Text] [Related]
51. Bile acid-induced apoptosis in hepatocytes is caspase-6-dependent.
Rust C; Wild N; Bernt C; Vennegeerts T; Wimmer R; Beuers U
J Biol Chem; 2009 Jan; 284(5):2908-2916. PubMed ID: 19017654
[TBL] [Abstract][Full Text] [Related]
52. Cell-specific inhibition of inducible nitric oxide synthase activation by leflunomide.
Jankovic V; Samardzic T; Stosic-Grujicic S; Popadic D; Trajkovic V
Cell Immunol; 2000 Feb; 199(2):73-80. PubMed ID: 10698616
[TBL] [Abstract][Full Text] [Related]
53. Leflunomide inhibits cytokine-induced DNA synthesis of rabbit synovial cells in culture.
Ju DW; Zheng QY; Wang HB; Fang J
Zhongguo Yao Li Xue Bao; 1994 May; 15(3):223-6. PubMed ID: 7976375
[TBL] [Abstract][Full Text] [Related]
54. Suppressive effect of leflunomide metabolite (A77 1726) on metalloproteinase production in IL-1beta stimulated rheumatoid synovial fibroblasts.
Migita K; Miyashita T; Ishibashi H; Maeda Y; Nakamura M; Yatsuhashi H; Ida H; Kawakami A; Aoyagi T; Kawabe Y; Eguchi K
Clin Exp Immunol; 2004 Sep; 137(3):612-6. PubMed ID: 15320915
[TBL] [Abstract][Full Text] [Related]
55. Low dose leflunomide activates PI3K/Akt signalling in erythroleukemia cells and reduces apoptosis induced by anticancer agents.
Leger DY; Liagre B; Beneytout JL
Apoptosis; 2006 Oct; 11(10):1747-60. PubMed ID: 16927021
[TBL] [Abstract][Full Text] [Related]
56. Immunosuppressants leflunomide and mycophenolic acid inhibit fibroblast IL-6 production by distinct mechanisms.
Miljkovic Dj; Samardzic T; Drakulic D; Stosic-Grujicic S; Trajkovic V
Cytokine; 2002 Aug; 19(4):181-6. PubMed ID: 12297111
[TBL] [Abstract][Full Text] [Related]
57. Measurement of the active leflunomide metabolite (A77 1726) by reverse-phase high-performance liquid chromatography.
Dias VC; Lucien J; LeGatt DF; Yatscoff RW
Ther Drug Monit; 1995 Feb; 17(1):84-8. PubMed ID: 7725383
[TBL] [Abstract][Full Text] [Related]
58. AKT activator SC79 protects hepatocytes from TNF-α-mediated apoptosis and alleviates d-Gal/LPS-induced liver injury.
Jing ZT; Liu W; Xue CR; Wu SX; Chen WN; Lin XJ; Lin X
Am J Physiol Gastrointest Liver Physiol; 2019 Mar; 316(3):G387-G396. PubMed ID: 30629471
[TBL] [Abstract][Full Text] [Related]
59. cAMP-GEF cytoprotection by Src tyrosine kinase activation of phosphoinositide-3-kinase p110 beta/alpha in rat hepatocytes.
Gates A; Hohenester S; Anwer MS; Webster CR
Am J Physiol Gastrointest Liver Physiol; 2009 Apr; 296(4):G764-74. PubMed ID: 19196950
[TBL] [Abstract][Full Text] [Related]
60. Leflunomide suppresses TNF-induced cellular responses: effects on NF-kappa B, activator protein-1, c-Jun N-terminal protein kinase, and apoptosis.
Manna SK; Mukhopadhyay A; Aggarwal BB
J Immunol; 2000 Nov; 165(10):5962-9. PubMed ID: 11067959
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
